Canopy Growth
OrganizationRelationship Network
Event Timeline
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
Constellation Brands
|
Financial |
7
|
3 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| 2017-01-01 | N/A | Constellation Brands' investment in Canopy Growth | Canada | View |
HOUSE_OVERSIGHT_024649.jpg
This document is page 13 of an Executive Summary from a 2017 Ackrell Capital investment report regarding the cannabis industry. It discusses the increase in strategic investor activity, citing investments by Constellation Brands and Scotts Miracle-Gro, while noting a continuing funding gap due to a lack of institutional support. The document outlines the investment outlook, noting that while billions were raised in 2017, most companies are in early development stages with revenues under $5 million. The document bears a 'HOUSE_OVERSIGHT_024649' stamp, suggesting it is part of a larger document production to the House Oversight Committee.
HOUSE_OVERSIGHT_024920.jpg
This document is a financial chart produced by Cowen Collaborative Insights dated February 25, 2019. It details the rating history and stock performance of Canopy Growth Corporation from April 2016 to January 2019, including specific price targets. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, and is watermarked for Michael Cella of Cowen.
HOUSE_OVERSIGHT_024917.jpg
This document is an addendum to a Cowen research report dated February 25, 2019, providing mandatory regulatory disclosures and certifications. It lists Canopy Growth, GW Pharmaceuticals, Tilray, and Turning Point Brands as subject companies and details Cowen's investment banking relationships, market making activities, and compensation policies related to these entities. The document also includes a standard disclaimer regarding the informational nature of the report, limitations of liability, and contact information for the compliance department.
HOUSE_OVERSIGHT_024912.jpg
This document is page 96 of a financial research report titled 'Cowen Collaborative Insights' dated February 25, 2019. It contains 'Figure 136 Cannabis Comp Table,' an appendix listing market data and valuations for various cannabis-related companies such as Aphria Inc, Aurora Cannabis Inc, and Level Brands Inc. The document bears a 'HOUSE_OVERSIGHT_024912' stamp, indicating it was part of a document production to the House Oversight Committee, likely obtained from the files of Michael Cella at Cowen.
HOUSE_OVERSIGHT_024900.jpg
This document is page 84 of a Cowen Collaborative Insights market research report dated February 25, 2019. It details the legal and business landscape of the medical cannabis industry in Chile and Colombia, listing various companies involved such as Dayacann, Tilray, and Canopy Growth. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was gathered as part of a congressional investigation, likely related to financial records or investment bank communications.
HOUSE_OVERSIGHT_024873.jpg
This document is page 57 of a Cowen Collaborative Insights report dated February 25, 2019, detailing the strategies of major Canadian cannabis companies (Aphria, Aurora, Canopy Growth, Cronos, Emblem, and Emerald Health) regarding the hemp and CBD markets. It aggregates quotes from CEO earnings calls and press releases concerning market expansion into Europe and the US, as well as strategic partnerships. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024819.jpg
A Cowen equity research report titled 'Cowen's Collective View of CBD - Ahead of the Curve Series,' dated February 25, 2019. The document analyzes the U.S. CBD market, projecting a $16 billion opportunity by 2025, and discusses consumer trends, scientific understanding, and hemp cultivation. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024819) and a watermark indicating it was intended for Michael Cella at Cowen.
HOUSE_OVERSIGHT_024764.jpg
This document is page 128 of a December 2017 Cannabis Investment Report by Ackrell Capital. It features a line graph tracking Canadian Cannabis Stock Price Performance against various indices from September 2016 to November 2017, highlighting market events such as the PM's legalization announcement and Constellation Brands' investment in Canopy Growth. The page bears the Bates stamp HOUSE_OVERSIGHT_024764, indicating it is part of a larger production of documents, likely related to congressional oversight, though no specific connection to Jeffrey Epstein or his associates is visible in the text of this specific page.
HOUSE_OVERSIGHT_024763.jpg
This document is page 127 of a report by Ackrell Capital titled 'Capital Markets for Cannabis Companies.' It provides a financial summary of Canadian publicly traded cannabis-related companies as of November 30, 2017, including market value and revenue data for companies on the TSX, TSXV, and CSE. The text also references the positive market impact of Prime Minister Justin Trudeau's legislative announcements and an investment by Constellation Brands into Canopy Growth. The document bears a 'HOUSE_OVERSIGHT' Bates stamp.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity